Hoog, Meredith
Maldonado, Juan M.
Wangia-Dixon, Ruth
Halpern, Rachel
Buysman, Erin
Gremel, Garrett W.
Huang, Ahong
Konig, Manige
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 13 December 2023
Accepted: 1 February 2024
First Online: 1 March 2024
Declarations
:
: Meredith Hoog, Manige Konig, and Juan M Maldonado are employees and minor stockholders of Eli Lilly and Company. Ahong Huang is an employee of Tigermed-BDM and is a paid consultant of Eli Lilly and has no relevant conflict of interests to declare. Rachel Halpern, Erin K Buysman, and Garrett W Gremel are employees of Optum, Inc. Ruth Wangia-Dixon was an employee of Optum, Inc. during the conduct of this research and is currently an employee of Elevance Health. Optum, Inc. conducted this study under a paid contract with Eli Lilly and Company.
: All study data were accessed in compliance with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act (HIPAA) of 1996. As this study used only de-identified data compliant with the HIPAA from the ORD, it was exempt from Institutional Review Board approval. The data supporting the study results were provided by Optum, Inc. and were used under license for this study.